Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target Lowered to $12.00 at The Goldman Sachs Group
Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) had its price objective reduced by The Goldman Sachs Group from $18.00 to $12.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have a neutral rating on the stock. A number of other research firms have also commented on PHAT. HC Wainwright reissued a […]
Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) had its price objective reduced by The Goldman Sachs Group from $18.00 to $12.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have a neutral rating on the stock. A number of other research firms have also commented on PHAT. HC Wainwright reissued a […]
